[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587889":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":45,"locations":51,"responsibleParty":266,"collaborators":34,"id":268,"slug":269,"hasResults":270,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":34,"eligibilityCriteria":274,"healthyVolunteers":275,"sex":276,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":34,"studyType":282,"phases":283,"briefSummary":285,"conditions":286,"keywords":34,"overallStatus":54,"whyStopped":34,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":297},{"fullName":5,"class":6},"TRex Bio, Inc.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"SAD - TRB-061","EXPERIMENTAL","Single ascending subcutaneous doses of TRB-061 in healthy participants",[13],"Drug: TRB-061",{"label":15,"type":10,"description":16,"interventionNames":17},"MAD - TRB-061","Multiple subcutaneous doses (Q4W for 8 weeks) in healthy participants",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Phase 1b - TRB-061","Multiple subcutaneous doses (Q4W for 12 weeks) in patients with moderate-to-severe AD",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Placebo Comparator","PLACEBO_COMPARATOR","Subcutaneous placebo (matching TRB-061 in each study part)",[27],"Drug: Placebo",[29,35,38,41],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","TRB-061","Single subcutaneous injection of TRB-061 at escalating doses",[9],null,{"type":30,"name":31,"description":36,"armGroupLabels":37,"otherNames":34},"Subcutaneous TRB-061 administered every 4 weeks for a total of 4 doses",[19],{"type":30,"name":31,"description":39,"armGroupLabels":40,"otherNames":34},"Subcutaneous TRB-061 administered every 4 weeks for 3 doses",[15],{"type":30,"name":42,"description":43,"armGroupLabels":44,"otherNames":34},"Placebo","Single and multiple subcutaneous doses of placebo matching TRB-061 in patients",[23],[46],{"name":47,"role":48,"phone":49,"phoneExt":34,"email":50},"Study Director","CONTACT","+1 (650) 567-5582","clinicaltrials@trex.bio",[52,71,86,100,113,128,139,153,170,185,195,210,225,239,253],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Paratus Clinical Research - Canberra Trial Clinic","RECRUITING","Belconnen","Australian Capital Territory","2617","Australia","AU",{"type":61,"coordinates":62},"Point",[63,64],149.06627,-35.23798,{"lat":64,"lon":63},[67],{"name":68,"role":48,"phone":69,"phoneExt":34,"email":70},"Amber Leah, Dr","1300 742 326","amber.leah@paratusclinical.com",{"facility":72,"status":54,"city":73,"state":74,"zip":75,"country":58,"countryCode":59,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Paratus Clinical Brisbane Pty Ltd","Albion","Brisbane","4010",{"type":61,"coordinates":77},[78,79],144.81724,-37.78017,{"lat":79,"lon":78},[82],{"name":83,"role":48,"phone":84,"phoneExt":34,"email":85},"Pi Lip Seet, Dr","0721119168","pilip.seet@paratusclinical.com",{"facility":87,"status":54,"city":88,"state":89,"zip":90,"country":58,"countryCode":59,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Paratus Clinical Research Western Sydney","Blacktown","New South Wales","2148",{"type":61,"coordinates":92},[93,94],150.91667,-33.76667,{"lat":94,"lon":93},[97],{"name":98,"role":48,"phone":69,"phoneExt":34,"email":99},"Ushma Narsai, Dr","ushma.narsai@paratusclinical.com",{"facility":101,"status":54,"city":102,"state":89,"zip":103,"country":58,"countryCode":59,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Paratus Clinical Research Central Coast","Kanwal","2259",{"type":61,"coordinates":105},[106,107],151.4911,-33.253,{"lat":107,"lon":106},[110],{"name":111,"role":48,"phone":69,"phoneExt":34,"email":112},"Ian Forsyth, Dr","ian.forsyth@paratusclinical.com",{"facility":114,"status":54,"city":115,"state":116,"zip":117,"country":58,"countryCode":59,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Cornerstone Centre for Clinical Research","Coorparoo","Queensland","4151",{"type":61,"coordinates":119},[120,121],153.05826,-27.49325,{"lat":121,"lon":120},[124],{"name":125,"role":48,"phone":126,"phoneExt":34,"email":127},"Young Jin Kim, Dr","0425 247 302","kim_youngjin@hotmail.com",{"facility":129,"status":130,"city":131,"state":132,"zip":133,"country":58,"countryCode":59,"cosmosGeoPoint":134,"geoPoint":138,"contacts":34},"CMAX Clinical Research Pty Ltd","ACTIVE_NOT_RECRUITING","Adelaide","South Australia","5000",{"type":61,"coordinates":135},[136,137],138.59863,-34.92866,{"lat":137,"lon":136},{"facility":140,"status":54,"city":141,"state":142,"zip":143,"country":58,"countryCode":59,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Paratus Clinical Research Melbourne","Melbourne","Victoria","3070",{"type":61,"coordinates":145},[146,147],144.96332,-37.814,{"lat":147,"lon":146},[150],{"name":151,"role":48,"phone":69,"phoneExt":34,"email":152},"Kianoosh Noori Samie, Dr","kianoosh.noorisamie@paratusclinical.com",{"facility":154,"status":54,"city":155,"state":156,"zip":157,"country":158,"countryCode":159,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Momentum Clinical Research Pukekohe","Pukekohe","Auckland","2120","New Zealand","NZ",{"type":61,"coordinates":161},[162,163],174.90363,-37.20196,{"lat":163,"lon":162},[166],{"name":167,"role":48,"phone":168,"phoneExt":34,"email":169},"Michelle Baker, Dr","+64 9 237 0121","Michelle.baker@momentumclinicalresearch.co.nz",{"facility":171,"status":54,"city":172,"state":173,"zip":174,"country":158,"countryCode":159,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Momentum Clinical Research Dunedin","Dunedin","Otago","9016",{"type":61,"coordinates":176},[177,178],170.50361,-45.87416,{"lat":178,"lon":177},[181],{"name":182,"role":48,"phone":183,"phoneExt":34,"email":184},"Sarah Hortop, Dr","+64 3 974 8170","Sarah.Hortop@momentumclinicalresearch.co.nz",{"facility":186,"status":54,"city":187,"state":188,"zip":189,"country":158,"countryCode":159,"cosmosGeoPoint":34,"geoPoint":34,"contacts":190},"Pacific Clinical Research Network-Tasman","Nelson","Tasman District","7011",[191],{"name":192,"role":48,"phone":193,"phoneExt":34,"email":194},"Claire Thurlow, Dr","+64 21 144 8740","clairethurlow@pcrn.co.nz",{"facility":196,"status":54,"city":197,"state":198,"zip":199,"country":158,"countryCode":159,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Clinical Trials New Zealand Ltd","Hamilton","Waikato Region","3204",{"type":61,"coordinates":201},[202,203],175.28333,-37.78333,{"lat":203,"lon":202},[206],{"name":207,"role":48,"phone":208,"phoneExt":34,"email":209},"Amy Stanway, Dr","+64 7 843 0105","amystanway@yahoo.co.nz",{"facility":211,"status":54,"city":212,"state":213,"zip":214,"country":158,"countryCode":159,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"Medical Research Institute of New Zealand","Newtown","Wellington Region","6021",{"type":61,"coordinates":216},[217,218],174.77935,-41.31115,{"lat":218,"lon":217},[221],{"name":222,"role":48,"phone":223,"phoneExt":34,"email":224},"Karen Oldfield, Dr","+64 4 805 0235","karen.oldfield@mrinz.ac.nz",{"facility":226,"status":54,"city":227,"state":213,"zip":228,"country":158,"countryCode":159,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"Pacific Clinical Research Network-Wellington","Upper Hutt","5018",{"type":61,"coordinates":230},[231,232],175.0502,-41.13827,{"lat":232,"lon":231},[235],{"name":236,"role":48,"phone":237,"phoneExt":34,"email":238},"Tim Humphrey, Dr","021653212","Tim.Humphrey@lctwellington.co.nz",{"facility":240,"status":54,"city":241,"state":213,"zip":242,"country":158,"countryCode":159,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"Momentum Clinical Research Kapiti","Waikanae","5036",{"type":61,"coordinates":244},[245,246],175.06667,-40.88333,{"lat":246,"lon":245},[249],{"name":250,"role":48,"phone":251,"phoneExt":34,"email":252},"Andrew Edwards, Dr","+64 4 908 1001","andrew.edwards@momentumclinicalresearch.co.nz",{"facility":254,"status":54,"city":156,"state":34,"zip":255,"country":158,"countryCode":159,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"Pacific Clinical Research Network-West Auckland","0600",{"type":61,"coordinates":257},[258,259],174.76349,-36.84853,{"lat":259,"lon":258},[262],{"name":263,"role":48,"phone":264,"phoneExt":34,"email":265},"Milan Radojevic, Dr","+64 9 883 0123","MilanRadojevic@pcrn.co.nz",{"type":267,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100587889","phase-1-phase-1a1b-study-of-trb-061-in-healthy-participants--patients-with-atopic-dermatitis-100587889",false,"NCT06934252","Phase 1a\u002F1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis","A Phase 1a\u002F1b Randomized, Double-Blind, Placebo-Controlled, 3-Part Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Doses of TRB-061 in Healthy Participants and in Patients With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Male or female participants aged 18 to 70 years, inclusive, at the time of informed consent.\n2. Body weight ≥50 kg and a body mass index (BMI)between 18.5 and 35.0 kg\u002Fm², inclusive.\n3. Participant is in good general health as determined by the investigator, based on medical history, physical examination, and clinical laboratory tests.\n4. For healthy participants (SAD and MAD): no clinically significant abnormalities in ECGs at screening.\n5. For participants in Phase 1b: Confirmed diagnosis of AD with onset of symptoms at least 1 year prior to Screening.\n6. Must be nonpregnant and nonlactating with negative pregnancy tests at screening and prior to dosing.\n7. Must be a non-smoker or ≤5 cigarettes per week for the past 6 months (SAD\u002FMAD only).\n8. For participants in Phase 1b: Moderate-to-severe AD at Screening and at Day 1 visit\n9. Agrees to abstain from the use of tetrahydrocannabinol (THC)-containing products while on study.\n\nExclusion Criteria:\n\n1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may put the participant at risk or interfere with study results.\n2. History or presence of any condition requiring systemic immunosuppressive or immunomodulatory therapy within a defined period before screening.\n3. Use of any biologic agent (e.g., monoclonal antibodies) within 3 months or 5 half-lives (whichever is longer) before Day 1.\n4. Participation in another investigational drug trial within 30 days or 5 half-lives of the prior investigational product (whichever is longer) before Day 1.\n5. History of hypersensitivity or allergic reaction to any component of the study drug or placebo formulation.\n6. Known active or latent tuberculosis (TB) infection. or history of incomplete TB treatment.\n7. Positive test at screening for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) RNA, or human immunodeficiency virus (HIV).\n8. Active infection or history of serious infections within 4 weeks prior to Day 1.\n9. Clinically significant ECG abnormalities (e.g., QTcF\\>470 ms) or other cardiac risk factors.\n10. Abnormal and clinically significant laboratory values at screening.\n11. Use of live vaccines within 4 weeks before Day 1.\n12. Use of systemic corticosteroids, immunosuppressants, or immunomodulatory drugs within protocol-defined washout periods (Part 3 only).\n13. Recent history of alcohol or drug abuse as defined per protocol.\n14. Use of tobacco\u002Fnicotine products beyond protocol-allowed limits (SAD and MAD).\n15. Positive cotinine test at check-in (SAD\u002FMAD only).\n16. Any other reason, in the opinion of the investigator or sponsor, that would make the participant unsuitable for participation in the study.\n17. Any medical or psychiatric condition that, in the opinion of the Investigator or Sponsor's medical monitor, would place the participant at risk, interfere with study participation, or interfere with the interpretation of study results.\n18. Surgery within the past 90 days prior to dosing as determined by the Investigator or Sponsor's medical monitor to be clinically relevant or planned surgery to be performed during the study and 30 days after the last dose of study drug",true,"ALL","18 Years","70 Years",{"count":280,"type":281},115,"ESTIMATED","INTERVENTIONAL",[284],"PHASE1","This Phase 1a\u002F1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with moderate-to-severe atopic dermatitis (AD). The number of dosing cohorts may be increased or decreased in Part 1 (SAD) or Part 2 (MAD).\n\nPart 1 (SAD): Healthy participants receiving single doses of TRB-061 or placebo.\n\nPart 2 (MAD): Healthy participants receiving multiple doses (3 doses over 8 weeks) of TRB-061 or placebo.\n\nPart 3 (Phase 1b): Participants with moderate-to-severe AD receiving repeated doses (4 doses over 12 weeks) of TRB-061 or placebo.",[287],"Moderate-to-severe Atopic Dermatitis","2026-06-15",{"date":290,"type":291},"2026-06-16","ACTUAL",{"date":293,"type":291},"2025-05-02",{"date":295,"type":281},"2028-02-29",{"name":5,"class":6},15]